Iris Lansdorp-Vogelaar Selected Research

Guaiac

1/2022	Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
1/2021	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe.
1/2019	Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
1/2017	Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
1/2017	Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
12/2015	European Code against Cancer, 4th Edition: Cancer screening.
9/2015	The impact of stratifying by family history in colorectal cancer screening programs.
8/2015	Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
6/2015	Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Iris Lansdorp-Vogelaar Research Topics

Disease

23	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 10/2009
17	Neoplasms (Cancer) 01/2022 - 04/2011
9	Adenoma (Adenomas) 01/2022 - 07/2011
2	Cystic Fibrosis (Mucoviscidosis) 01/2018 - 12/2017
2	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 01/2013
1	Polyps 01/2022
1	COVID-19 01/2022
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 10/2021
1	Testicular Neoplasms (Testicular Cancer) 02/2021
1	Carcinogenesis 02/2021
1	Gastroesophageal Reflux (GERD) 09/2017
1	Hodgkin Disease (Hodgkin's Disease) 02/2017
1	Barrett Esophagus (Barrett's Esophagus) 01/2017
1	Adenocarcinoma 01/2017
1	Abdominal Pain (Pain, Abdominal) 01/2016

Drug/Important Bio-Agent (IBA)

9	GuaiacIBA 01/2022 - 06/2015
8	Calcibiotic Root Canal SealerIBA 01/2022 - 07/2011
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 09/2010
4	Hemoglobins (Hemoglobin)IBA 01/2019 - 12/2011
4	Biomarkers (Surrogate Marker)IBA 01/2018 - 06/2014
3	GoldIBA 01/2020 - 11/2018
2	Indicators and Reagents (Reagents)IBA 01/2022 - 01/2019
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2018 - 01/2013
1	SuspensionsIBA 01/2022
1	PlatinumIBA 02/2021
1	Cisplatin (Platino)FDA LinkGeneric 02/2021
1	Trefoil Factor-3IBA 09/2017
1	Procarbazine (Matulane)FDA Link 02/2017
1	amphetaminil (AN 1)IBA 01/2017
1	Carbon DioxideIBA 01/2016
1	ORALIT (ORS)IBA 06/2013
1	Dihydrotachysterol (AT 10)IBA 06/2013
1	IS 33IBA 01/2013
1	SolutionsIBA 07/2011
1	Biological ProductsIBA 04/2011

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 02/2021 - 10/2009
2	Radiotherapy 11/2019 - 02/2017
2	Transplantation 01/2018 - 12/2017
1	Hysterectomy 10/2021
1	Aftercare (After-Treatment) 02/2017
1	Therapeutics 02/2017
1	Radiofrequency Ablation 01/2017